Compare LVWR & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LVWR | SIGA |
|---|---|---|
| Founded | 2022 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 444.7M | 487.7M |
| IPO Year | N/A | 1997 |
| Metric | LVWR | SIGA |
|---|---|---|
| Price | $2.67 | $6.75 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 167.7K | ★ 325.0K |
| Earning Date | 02-10-2026 | 03-10-2026 |
| Dividend Yield | N/A | ★ 8.96% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.03 |
| Revenue | $25,078,000.00 | ★ $172,249,641.00 |
| Revenue This Year | $249.13 | N/A |
| Revenue Next Year | $98.53 | $132.36 |
| P/E Ratio | ★ N/A | $6.50 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.93 | $4.95 |
| 52 Week High | $9.04 | $9.62 |
| Indicator | LVWR | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 35.89 | 46.79 |
| Support Level | $2.16 | $6.51 |
| Resistance Level | $2.62 | $7.11 |
| Average True Range (ATR) | 0.31 | 0.22 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 19.53 | 20.14 |
LiveWire Group Inc is an all-electric vehicle company. It sells electric vehicles and related parts and accessories and apparel in the United States and certain international markets. The company's segment includes Electric Motorcycles and STACYC. Electric Motorcycles segment sells electric motorcycles, related parts and accessories and apparel in the United States and certain international markets; STACYC segment sells electric balance bikes for kids, related parts and accessories and apparel in the United States and certain international markets. LiveWire generates revenue from the sale of electric motorcycles, Parts, accessories and apparel. Majority of revenue is from USA.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.